Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris
In pemphigus vulgaris (PV), IgG autoantibodies against the ectodomain of desmoglein 3 (Dsg3) have been shown to be directly responsible for the loss of keratinocyteadhesion. The aim of the present study was to study the effect of the B cell depleting anti-CD20 monoclonal antibody, rituximab, on the...
Saved in:
Main Authors: | Ralf Müller (Author), Nicolas Hunzelmann (Author), Vera Baur (Author), Guido Siebenhaar (Author), Elke Wenzel (Author), Rüdiger Eming (Author), Andrea Niedermeier (Author), Philippe Musette (Author), Pascal Joly (Author), Michael Hertl (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2010-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Faster IgG4 Depletion Kinetics Observed for Anti-Desmoglein 3 Autoantibodies Following Rituximab Treatment in Patients with Pemphigus Vulgaris
by: Katharina Boch, et al.
Published: (2022) -
Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
by: Stephanie Del Rio Navarrete Biot, et al.
Published: (2014) -
Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris
by: Sharon Baum, et al.
Published: (2020) -
Autoantibodies other than anti-desmogleins in pemphigus vulgaris patients
by: Marwah Adly Saleh, et al.
Published: (2017) -
Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
by: Gabrielle Benesh, BS, et al.
Published: (2021)